BACKGROUND: The authors investigated whether coexpression and localization of E-cadherin (E-cad) and epidermal growth factor receptor (EGFR) had predictive and/or prognostic correlations with lymph node metastasis and/or survival in patients with squamous cell carcinoma of the head and neck (SCCHN). METHODS: Immunohistochemistry (IHC) of archival tissue was performed to measure expression of EGFR and E-cad in surgical specimens of SCCHN (n = 143) that included primary tumors (PTs) with positive lymph nodes (Tu+Met) and their paired lymph node metastases (LnMet), PTs with negative lymph nodes (Tu(-Met)), and benign tissue biopsies as normal controls. IHC staining was quantified as a weighted index and as the ratio of membrane to cytoplasmic staining. Correlative expression between EGFR and E-cad also was examined in SCCHN cell lines by immunoblotting and immunofluorescence analyses. RESULTS: Three distinct expression patterns of EGFR and E-cad were observed. Membrane localization of E-cad was significantly lower in the Tu+Met group than in the Tu(-Met) group (P = .01) and was associated inversely with lymph node status (P = .009). Wilcoxon analysis of the combined markers demonstrated that expression and/or membrane localization of EGFR and E-cad were correlated with disease-free survival and overall survival in patients with SCCHN. The study of SCCHN cell lines demonstrated that cells with positive but low EGFR expression and with negative E-cad expression were relatively resistant to the EGFR tyrosine kinase inhibitor erlotinib. CONCLUSIONS: The current study suggested that examining not only the expression but also the localization of EGFR and E-cad simultaneously may have clinical relevance in predicting lymph node metastasis, patient survival, and response to EGFR-targeted therapy in patients with SCCHN. (Copyright) 2008 American Cancer Society.
BACKGROUND: The authors investigated whether coexpression and localization of E-cadherin (E-cad) and epidermal growth factor receptor (EGFR) had predictive and/or prognostic correlations with lymph node metastasis and/or survival in patients with squamous cell carcinoma of the head and neck (SCCHN). METHODS: Immunohistochemistry (IHC) of archival tissue was performed to measure expression of EGFR and E-cad in surgical specimens of SCCHN (n = 143) that included primary tumors (PTs) with positive lymph nodes (Tu+Met) and their paired lymph node metastases (LnMet), PTs with negative lymph nodes (Tu(-Met)), and benign tissue biopsies as normal controls. IHC staining was quantified as a weighted index and as the ratio of membrane to cytoplasmic staining. Correlative expression between EGFR and E-cad also was examined in SCCHN cell lines by immunoblotting and immunofluorescence analyses. RESULTS: Three distinct expression patterns of EGFR and E-cad were observed. Membrane localization of E-cad was significantly lower in the Tu+Met group than in the Tu(-Met) group (P = .01) and was associated inversely with lymph node status (P = .009). Wilcoxon analysis of the combined markers demonstrated that expression and/or membrane localization of EGFR and E-cad were correlated with disease-free survival and overall survival in patients with SCCHN. The study of SCCHN cell lines demonstrated that cells with positive but low EGFR expression and with negative E-cad expression were relatively resistant to the EGFR tyrosine kinase inhibitor erlotinib. CONCLUSIONS: The current study suggested that examining not only the expression but also the localization of EGFR and E-cad simultaneously may have clinical relevance in predicting lymph node metastasis, patient survival, and response to EGFR-targeted therapy in patients with SCCHN. (Copyright) 2008 American Cancer Society.
Authors: Dongsheng Wang; Susan Müller; A R M Ruhul Amin; Donghai Huang; Ling Su; Zhongliang Hu; Mohammad Aminur Rahman; Sreenivas Nannapaneni; Lydia Koenig; Zhengjia Chen; Mourad Tighiouart; Dong M Shin; Zhuo G Chen Journal: Clin Cancer Res Date: 2012-07-24 Impact factor: 12.531
Authors: Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis Journal: Clin Cancer Res Date: 2010-04-13 Impact factor: 12.531
Authors: Seth A Brodie; Ge Li; Adam El-Kommos; Hyunseok Kang; Suresh S Ramalingam; Madhusmita Behera; Khanjan Gandhi; Jeanne Kowalski; Gabriel L Sica; Fadlo R Khuri; Paula M Vertino; Johann C Brandes Journal: Cancer Prev Res (Phila) Date: 2014-01-17
Authors: Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen Journal: Clin Cancer Res Date: 2013-02-19 Impact factor: 12.531
Authors: Yuhong Du; Zijian Li; Lian Li; Zhuo Georgia Chen; Shi-Yong Sun; Peifang Chen; Dong M Shin; Fadlo R Khuri; Haian Fu Journal: J Recept Signal Transduct Res Date: 2009 Impact factor: 2.092
Authors: Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240
Authors: Songqing Fan; Susan Müller; Zhuo Georgia Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun Journal: Cancer Biol Ther Date: 2013-01-28 Impact factor: 4.742